Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Blood Biomarker Panels for the Early Prediction of Stroke‐Associated Complications

  • Faura, Júlia
  • Bustamante, Alejandro
  • Reverté, Silvia
  • García Berrocoso, Teresa
  • Millán, Mónica
  • Castellanos, Mar
  • Lara Rodríguez, Blanca
  • Zaragoza, Josep
  • Ventura, Oriol
  • Hernández Pérez, María
  • Van Eendenburg, Cecile
  • Cardona, Pere-Joan
  • López Cancio, Elena
  • Cánovas Vergé, David
  • Serena, Joaquín
  • Rubiera, Marta
  • Dávalos, Antoni
  • Montaner, Joan
Background Acute decompensated heart failure (ADHF) and respiratory tract infections (RTIs) are potentially life-threatening complications in patients experiencing stroke during hospitalization. We aimed to test whether blood biomarker panels might predict these complications early after admission. Methods and Results Nine hundred thirty-eight patients experiencing ischemic stroke were prospectively recruited in the Stroke-Chip study. Post-stroke complications during hospitalization were retrospectively evaluated. Blood samples were drawn within 6 hours after stroke onset, and 14 biomarkers were analyzed by immunoassays. Biomarker values were normalized using log-transformation and Z score. PanelomiX algorithm was used to select panels with the best accuracy for predicting ADHF and RTI. Logistic regression models were constructed with the clinical variables and the biomarker panels. The additional predictive value of the panels compared with the clinical model alone was evaluated by receiver operating characteristic curves. An internal validation through a 10-fold cross-validation with 3 repeats was performed. ADHF and RTI occurred in 19 (2%) and 86 (9.1%) cases, respectively. Three-biomarker panels were developed as predictors: vascular adhesion protein-1 >5.67, NT-proBNP (N-terminal pro-B-type natriuretic peptide) >4.98 and d-dimer >5.38 (sensitivity, 89.5%; specificity, 71.7%) for ADHF; and interleukin-6 >3.97, von Willebrand factor >3.67, and d-dimer >4.58 (sensitivity, 82.6%; specificity, 59.8%) for RTI. Both panels independently predicted stroke complications (panel for ADHF: odds ratio [OR] [95% CI], 10.1 [3-52.2]; panel for RTI: OR, 3.73 [1.95-7.14]) after adjustment by clinical confounders. The addition of the panel to clinical predictors significantly improved areas under the curve of the receiver operating characteristic curves in both cases. Conclusions Blood biomarkers could be useful for the early prediction of ADHF and RTI. Future studies should assess the usefulness of these panels in front of patients experiencing stroke with respiratory symptoms such as dyspnea.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Common and specific proteins and pathways in heart and cerebral ischemia

  • Palà, Elena
  • García-Rodríguez, Paula
  • Bustamante, Alejandro
  • Penalba, Anna
  • Lamana-Vallverdú, Marcel
  • Guamán-Pilco, Daisy R.
  • Delgado, Pilar
  • Riba, Iolanda
  • Jiménez-Balado, Joan
  • Planas, Alejandra
  • Simó-Servat, Olga
  • Escudero-Martínez, Irene
  • Montaner, Joan
[Objective] To understand the similarities and differences between acute ischemic stroke and acute myocardial infarction (AMI) to help in the development of specific or common treatment strategies., [Methods] Using an aptamer-based proteomic array, we measured and compared 1310 circulating proteins in the blood of 40 patients with AIS, 9 patients with AMI, and 31 healthy controls. Pathway enrichment analysis was performed using GSEA and g:profiler., [Results] Ninety-four proteins were differentially expressed in AIS, and 284 were differentially expressed in AMI. Of these, 8 were specific to cerebral ischemia, and 197 were specific to myocardial infarction. Forty-two proteins were altered in both ischemia processes. Most altered pathways in AIS could be classified as immune response, cell cycle processing, molecular transport, or signaling. Pathways altered in AMI were mostly related to lipid metabolism and transport, highlighting cholesterol metabolic processes and estrogen signaling. In both types of ischemia, we found pathways related to metabolism, specifically purine metabolism, and signaling processes, such as TNF signaling or MAPK1/3., [Conclusions] The present study revealed proteins and pathways that were specifically altered in cerebral ischemia, in cardiac ischemia, or in both diseases, providing information on the similarities and differences of ischemic conditions. The role of common and specific proteins and pathways should be explored in detail to find possible therapeutic targets., This work was supported by the Instituto de Salud Carlos III (PI18/00804). The Neurovascular research laboratory is part of the Spanish stroke research RICORS (RD16/0019/00021). Also, part of the authors was funded by the European Union's Horizon 2020 research and innovation program (grant agreements 847770, 754517, and 733379). Also, the funding of the studies from which patients were used are detailed: PRECISED study was supported by an Integrative Excellence Project by the Spanish Institute of Health, Instituto de Salud Carlos III, grant PIE 2013/27, CIBER CV (Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares), CIBERDEM (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas asociadas), and the European Regional Development Fund (ERDF- FEDER); PARIAS study was funded by the Spanish Ministry of Economy, Industry and Competitiveness (Grant RTC-2016-5300-1), the Junta de Andalucía (Grant PIN- 0144-2016), the European Project ITRIBIS, and the Fundación Cajasol; COMBAT-MI was sponsored with a Grant from Instituto de Salud Carlos III (PIE 13/00027), and a Grant from Generalitat de Catalunya (PERIS SLT/2381/2016)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genomic analysis of intracranial and subcortical brain volumes yields polygenic scores accounting for variation across ancestries

  • García-Marín, Luis M.
  • Campos, Adrian I.
  • Diaz-Torres, Santiago
  • Crespo-Facorro, Benedicto
  • Romero García, Rafael
  • Tordesillas-Gutiérrez, Diana
  • Vázquez-Bourgon, Javier
García-Marín, Luis M.; Campos, Adrian I.; Diaz-Torres, Santiago; et al., Subcortical brain structures are involved in developmental, psychiatric and neurological disorders. Here we performed genome-wide association studies meta-analyses of intracranial and nine subcortical brain volumes (brainstem, caudate nucleus, putamen, hippocampus, globus pallidus, thalamus, nucleus accumbens, amygdala and the ventral diencephalon) in 74,898 participants of European ancestry. We identified 254 independent loci associated with these brain volumes, explaining up to 35% of phenotypic variance. We observed gene expression in specific neural cell types across differentiation time points, including genes involved in intracellular signaling and brain aging-related processes. Polygenic scores for brain volumes showed predictive ability when applied to individuals of diverse ancestries. We observed causal genetic effects of brain volumes with Parkinson's disease and attention-deficit/hyperactivity disorder. Findings implicate specific gene expression patterns in brain development and genetic variants in comorbid neuropsychiatric disorders, which could point to a brain substrate and region of action for risk genes implicated in brain diseases., This project has received funding from the European Union's Horizon 2020 Research and Innovation Programme under the Specific Grant Agreement 945539 (Human Brain Project SGA3). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643417, No 640643, and No 667375 and 754517. IMAGEN was funded by the European Union-funded FP6 Integrated Project IMAGEN (LSHM-CT- 2007-037286). The MCIC study was supported by the National Institutes of Health (NIH/NCRR P41RR14075 and R01EB005846), the Department of Energy (DE-FG02-99ER62764). NeuroIMAGE also received funding from the European Community’s Seventh Framework Programme (FP7/2007– 2013) under grant agreements n° 602805 (Aggressotype), n° 278948 (TACTICS), and n° 602450 (IMAGEMEND), and from the European Community’s Horizon 2020 Programme (H2020/2014– 2020) under grantagreements n°643051(MiND), n° 667302 (CoCA), and n° 728018 (Eat2beNICE). Additional support is received from the European Community's Seventh Framework Programme (FP7/2007– 2013) under grant agreements nº 602805 (Aggressotype), nº 603016 (MATRICS), nº 602450 (IMAGEMEND), and nº 278948 (TACTICS), and from the European Community's Horizon 2020 Programme (H2020/2014– 2020) under grant agreements nº 643051 (MiND) and nº 667302(CoCA). Erasmus Rucphen family study (ERF): The ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by the European Commission under the programme "Quality of Life and Management of the Living Resources" of 5th Framework Programme (no.QLG2-CT-2002-01254). the European Science Foundation (ESF, EU/QLRT-2001-01254), the European Community’s Seventh Framework Programme (FP7- HEALTH-F4-2007-2013, grant 01413: ENGAGE and grant 602768: ACTION); the European Research Council (ERC Starting 284167, ERC Consolidator 771057, ERC Advanced 230374). The Horizon 2020 supported programme CANDY Grant No. 847818). European Community’s Horizon 2020 Programme (H2020/2014– 2020) under grant agreement n° 847879 (PRIME). European Research Council under the European Union's Horizon 2020 research and Innovation program (ERC StG, Grant 802998). This work was supported by Fundación Marqués de Valdecilla, Instituto de investigación sanitaria Valdecilla., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial

  • Veltkamp, Roland
  • Korompoki, Eleni
  • Harvey, Kirsten H.
  • Harvey, Emily R.
  • Fießler, Cornelia
  • Malzahn, Uwe
  • Rücker, Viktoria
  • Montaner, Joan
  • Caso, Valeria
  • Sibon, Igor
  • Ringleb, Peter
  • Halse, Omid
  • Hügen, Klemens
  • Ullmann, Sabine
  • Schuhmann, Carolin
  • Todd, Gabriele Putz
  • Haas, Kirsten
  • Palà, Elena
  • Debette, Stéphanie
  • Lachaize, Morgane
  • D'Aoust, Tim
  • Enzinger, Christian
  • Ropele, Stefan
  • Fandler-Höfler, Simon
  • Haidegger, Melanie
  • Wang, Yanzhong
  • Wafa, Hatem A.
  • Cancelloni, Virginia
  • Mosconi, Maria Giulia
  • Lip, Gregory Y. H.
  • Lane, Deirdre A.
  • Haefeli, Walter E.
  • Foerster, Kathrin I.
  • Wurmbach, Viktoria S
  • Nielsen, Peter Brønnum
  • Hajjar, Karim
  • Müller, Patrick
  • Poli, Sven
  • Purrucker, Jan
  • Laible, Mona
  • D'Anna, Lucio
  • Silva, Yolanda
  • de Torres Chacon, Reyes
  • Martínez-Sánchez, Patricia
  • Boulanger, Marion
  • Norrving, Bo
  • Paré, Guillaume
  • Wachter, Rolf
  • Ntaios, George
  • Wolfe, Charles D. A.
  • Heuschmann, Peter U.
[Background] Direct oral anticoagulants (DOACs) reduce the rate of thromboembolism in patients with atrial fibrillation but the benefits and risks in survivors of intracerebral haemorrhage are uncertain. We aimed to determine whether DOACs reduce the risk of ischaemic stroke without substantially increasing the risk of recurrent intracerebral haemorrhage., [Methods] PRESTIGE-AF is a multicentre, open-label, randomised, phase 3 trial conducted at 75 hospitals in six European countries. Eligible patients were aged 18 years or older with spontaneous intracerebral haemorrhage, atrial fibrillation, an indication for anticoagulation, and a score of 4 or less on the modified Rankin Scale. Patients were randomly assigned (1:1) to a DOAC or no anticoagulation, stratified by intracerebral haemorrhage location and sex. Only the events adjudication committee was masked to treatment allocation. The coprimary endpoints were first ischaemic stroke and first recurrent intracerebral haemorrhage. Hierarchical testing for superiority and non-inferiority, respectively, was performed in the intention-to-treat population. The margin to establish non-inferiority regarding intracerebral haemorrhage was less than 1·735. The safety analysis was done in the intention-to-treat population. The trial is registered with ClinicalTrials.gov, NCT03996772, and is complete., [Findings] Between May 31, 2019, and Nov 30, 2023, 319 participants were enrolled and 158 were randomly assigned to the DOAC group and 161 to the no anticoagulant group. Patients' median age was 79 years (IQR 73–83). 113 (35%) of 319 patients were female and 206 (65%) were male. Median follow-up was 1·4 years (IQR 0·7–2·3). First ischaemic stroke occurred less frequently in the DOAC group than in the no anticoagulant group (hazard ratio [HR] 0·05 [95% CI 0·01–0·36]; log-rank p<0·0001). The rate of all ischaemic stroke events was 0·83 (95% CI 0·14–2·57) per 100 patient-years in the DOAC group versus 8·60 (5·43–12·80) per 100 patient-years in the no anticoagulant group. For first recurrent intracerebral haemorrhage, the DOAC group did not meet the prespecified HR for the non-inferiority margin of less than 1·735 (HR 10·89 [90% CI 1·95–60·72]; p=0·96). The event rate of all intracerebral haemorrhage was 5·00 (95% CI 2·68–8·39) per 100 patient-years in the DOAC group versus 0·82 (0·14–2·53) per 100 patient years in the no anticoagulant group. Serious adverse events occurred in 70 (44%) of 158 patients in the DOAC group and 89 (55%) of 161 patients in the no anticoagulant group. 16 (10%) patients in the DOAC group and 21 (13%) patients in the no anticoagulant group died., [Interpretation] DOACs effectively prevent ischaemic strokes in survivors of intracerebral haemorrhage with atrial fibrillation but a part of this benefit is offset by a substantially increased risk of recurrent intracerebral haemorrhage. To optimise stroke prevention in these vulnerable patients, further evidence from ongoing trials and a meta-analysis of randomised data is needed, as well as the evaluation of safer medical or mechanical alternatives for selected patients., This study was sponsored by Imperial College London and was funded by the European Commission as part of the Horizon 2020 research and innovation programme (grant 754517). We thank all participants, their relatives and carers, the outcome event adjudicators, the trial steering committee, the external ethics advisory committee, the scientific advisers, and the data safety and monitoring board., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuroimaging Markers Associated With Recurrent Stroke in Intracerebral Hemorrhage and Atrial Fibrillation: Secondary Analysis of PRESTIGE-AF

  • Fandler-Höfler, Simon
  • Ropele, Stefan
  • Gattringer, Thomas
  • Haidegger, Melanie
  • Pinter, Daniela
  • Kneihsl, Markus
  • Korompoki, Eleni
  • Montaner, Joan
  • Caso, Valeria
  • Ringleb, Peter Arthur
  • Sibon, Igor
  • Halse, Omid
  • Harvey, Kirsten
  • Fießler, Cornelia
  • Wolfe, C D A
  • Heuschmann, Peter U
  • Veltkamp, Roland
  • Enzinger, Christian
[Background and Objectives] Anticoagulation in patients with intracerebral hemorrhage (ICH) and atrial fibrillation reduces the risk of ischemic stroke (IS), but also potentially causes an excess risk of recurrent ICH. In this context, we assessed the role of neuroimaging in identifying patients with particular susceptibility to IS or ICH, potentially allowing for individualized risk stratification., [Methods] In PRESTIGE-AF, a prospective, randomized clinical trial conducted across 75 hospitals in 6 European countries, participants with spontaneous ICH and atrial fibrillation were randomized to treatment with direct oral anticoagulants or no anticoagulation. Within a prespecified imaging subanalysis, we centrally assessed brain CT and MRI scans at baseline using established scales and definitions. We performed Cox regression analyses to investigate associations of neuroimaging findings with recurrent ICH and IS., [Results] PRESTIGE-AF included 319 patients, and 313 had neuroimaging of sufficient quality (median age 79 years, 35.5% female). MRI was available in 170 patients (54.3%). During a median follow-up of 1.4 years, 13 patients had recurrent ICH and 22 patients had IS. ICH recurrence was not associated with lobar vs nonlobar hematoma location or the overall category of probable cerebral amyloid angiopathy (p > 0.2). However, there was an increased risk of recurrent ICH in patients with cortical superficial siderosis (hazard ratio [HR] 7.7, 95% CI 1.4–42.2) and chronic intracerebral macrohemorrhages on MRI (HR 9.1, 95% CI 1.8–46.8). Patients with nonlobar ICH were at increased risk of IS (HR 9.1, 95% CI 1.2–67.7)., [Discussion] Neuroimaging contributes to the identification of patients with ICH and atrial fibrillation at particularly high risk of recurrent ICH or IS, emphasizing its role in clinical decision making. MRI allows for the assessment of relevant neuroimaging markers that can aid the risk assessment in affected patients. Major study limitations include the modest number of outcome events, with confirmation of our findings needed in larger collaborations., This study was funded by European Union's Horizon 2020 Research and Innovation Program under Grant Agreement No. 754517., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Personalized Medicine, Public Health and Patient-Centred Aspects in the Prevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation (PRESTIGE-AF) Project

  • Harvey, Kirsten H.
  • Korompoki, Eleni
  • Harvey, Emily R.
  • Fießler, Cornelia
  • Malzahn, Uwe
  • Hügen, Klemens
  • Ullmann, Sabine
  • Schuhmann, Carolin
  • Putz Todd, Gabriele
  • Montaner, Joan
  • Penalba, Anna
  • Guamán-Pilco, Daisy R.
  • Sibon, Igor
  • Debette, Stephanie
  • D'Aoust, Timothy
  • Lachaize, Morgane
  • Enzinger, Christian
  • Ropele, Stefan
  • Fandler-Höfler, Simon
  • Ruecker, Viktoria
  • Haas, Kirsten
  • Nielsen, Peter B.
  • Wolfe, Charles
  • Wang, Yanzhong
  • Wafa, Hatem
  • Caso, Valeria
  • Mosconi, Maria Giulia
  • Lip, Gregory Y. H.
  • Lane, Deirdre A.
  • Haefeli, Walter E.
  • Foerster, Kathrin I.
  • Wurmbach, Viktoria S.
  • Ringleb, Peter
  • Heuschmann, Peter U.
  • Veltkamp, Roland
Invited Clinical Focus, 5, Although systematic reviews and meta-analysis of observational studies have suggested a benefit of oral anticoagulation (OAC) for ischaemic stroke prevention without a significant increase in recurrent ICH, experts agree that more evidence is required from randomized controlled trials (RCTs).1,2 PRESTIGE-AF is a European Union Horizon 2020 funded project with a consortium of 12 institutions across 7 countries since 2019 (►Fig. 1). The aim is to explore optimal stroke prevention strategies for intracerebral haemorrhage (ICH) survivors with atrial fibrillation (AF), investigating the balance between the risk of ischaemic stroke against the risk of recurrent ICH., All the authors received funding from European Union’s Horizon 2020 research and innovation programme under grant agreement No. 754517 (PRESTIGE-AF). E.K. received Speaker Honoraria/Advisory boards/Travel grants from Amgen, AstraZeneca, Bayer, Elpen, Innovis, Pfizer, Sanofi. S.F.-H. received Honoraria/Travel grant from AstraZeneca. P.B.N. received Institutional support by grants of Daiichi Sankyo and Consultancy fees from Daiichi-Sankoy, Bayer; Speaker Honoraria/Advisory boards: SERVIER, Baye. Y.W. and H.W. received funding from The National Institute for Health and Care Research (NIHR) under its Program Grants for Applied Research (NIHR202339). V.C. received Consultancy from Bayer Steering Committee Oceanic AF; Speakers from Bayer, BMS-Pfizer alliance and DaiichiSankyo; serve as a leadership role from WSO Treasurer. D.A.L. received Institutional support for investigator-initiated quality improvement grants from Bristol-Myers Squibb and Pfizer; Speaker fees from Bayer, Boehringer Ingelheim, and Bristol-Myers Squibb/Pfizer; Consultancy fees from Bristol-Myers Squibb and Boehringer Ingelheim; all outside the submitted work. W.E.H. received institutional support by grants from Boehringer Ingelheim and Daiichi-Sankyo. P.R. received institution support by Boehringer Ingelheim, Bayer; Speaker fees from Boehringer Ingelheim, Bayer, Pfizer; Participation DSMB/Advisory board: CLOSURE-AF, NISCI. P.U.H. received institutional research grants by German Ministry of Research and Education, German Research Foundation, Federal Joint Committee (G-BA) within the Innovation fund, German Cancer Aid, German Heart Foundation, Bavarian State, Robert Koch Institute, University Hospital Heidelberg. R.V. received Speaker Honoraria/Advisory boards from AstraZeneca, Bayer, BMS-Pfizer alliance; Research support: Bayer, BMS-Pfizer alliance, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Biogen. All other authors declared no conflict of interest., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Prevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation: Rationale and Design for PRESTIGE-AF Trial

  • Heuschmann, Peter
  • Malzahn, Uwe
  • Hügen, Klemens
  • Montaner Villalonga, Joan
  • Korompoki, Eleni
  • Harvey, Kirsten
  • Fiessler, Cornelia
Prevention of stroke; Intracerebral haemorrhage; Atrial fibrillation, Prevenció de l'ictus; Hemorràgia intracerebral; Fibril·lació auricular, Prevención del ictus; Hemorragia intracerebral; Fibrilación auricular, Adequate secondary prevention in survivors of intracerebral hemorrhage (ICH) who also have atrial fibrillation (AF) is a long-standing clinical dilemma because these patients are at increased risk of recurrent ICH as well as of ischemic stroke. The efficacy and safety of oral anticoagulation, the standard preventive medication for ischemic stroke patients with AF, in ICH patients with AF are uncertain. PRESTIGE-AF is an international,phase3b,multi-center,randomized,open,blindedend-pointassessment (PROBE)clinical trial that compared the efficacyandsafetyofdirectoralanticoagulants (DOACs) with no DOAC(either no antithrombotic treatment or any antiplatelet drug). Randomization occurred in a 1:1 ratio and stratification was based on ICH location and sex. The two co-primary binary endpoints included ischemic stroke and recurrent ICH which will be analyzed hierarchically according to the intention-to-treat principle. Secondary efficacy endpoints encompassed all-stroke and systemic embolism, allcause and cardiovascular mortality, major adverse cardiac events, and net clinical benefit. Secondary safety endpoints included any major hemorrhage and intracranial hemorrhage. All outcome events were adjudicated by an independent committee. Results of PRESTIGE-AF are expected to support risk-adjusted secondary prevention in ICH survivors with AF and to inform clinical guideline recommendations., PRESTIGE-AF is a clinical trial of investigational medicinal products sponsored by Imperial College London. The PRESTIGE-AF trial is managed by the coordinating team at Imperial College London. The data management, central data monitoring, and statistical analysis are provided by The Clinical Trial Centre at the University Hospital of Wuerzburg. The clinical trial is part of a Horizon 2020 project with a consortium of 12 institutions across Europe. This project has received funding from the European Union's Horizon 2020 research and innovation program under Grant Agreement No. 754517.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Blood Biomarker Panels for the Early Prediction of Stroke‐Associated Complications

  • Faura, Júlia
  • Bustamante, Alejandro
  • Reverté, Silvia
  • García Berrocoso, Teresa
  • Millán, Mónica
  • Castellanos, Mar
  • Lara Rodríguez, Blanca
  • Zaragoza, Josep
  • Ventura, Oriol
  • Hernández Pérez, María
  • Van Eendenburg, Cecile
  • Cardona, Pere-Joan
  • López Cancio, Elena
  • Cánovas Vergé, David
  • Serena, Joaquín
  • Rubiera, Marta
  • Dávalos, Antoni
  • Montaner, Joan
Background Acute decompensated heart failure (ADHF) and respiratory tract infections (RTIs) are potentially life-threatening complications in patients experiencing stroke during hospitalization. We aimed to test whether blood biomarker panels might predict these complications early after admission. Methods and Results Nine hundred thirty-eight patients experiencing ischemic stroke were prospectively recruited in the Stroke-Chip study. Post-stroke complications during hospitalization were retrospectively evaluated. Blood samples were drawn within 6 hours after stroke onset, and 14 biomarkers were analyzed by immunoassays. Biomarker values were normalized using log-transformation and Z score. PanelomiX algorithm was used to select panels with the best accuracy for predicting ADHF and RTI. Logistic regression models were constructed with the clinical variables and the biomarker panels. The additional predictive value of the panels compared with the clinical model alone was evaluated by receiver operating characteristic curves. An internal validation through a 10-fold cross-validation with 3 repeats was performed. ADHF and RTI occurred in 19 (2%) and 86 (9.1%) cases, respectively. Three-biomarker panels were developed as predictors: vascular adhesion protein-1 >5.67, NT-proBNP (N-terminal pro-B-type natriuretic peptide) >4.98 and d-dimer >5.38 (sensitivity, 89.5%; specificity, 71.7%) for ADHF; and interleukin-6 >3.97, von Willebrand factor >3.67, and d-dimer >4.58 (sensitivity, 82.6%; specificity, 59.8%) for RTI. Both panels independently predicted stroke complications (panel for ADHF: odds ratio [OR] [95% CI], 10.1 [3-52.2]; panel for RTI: OR, 3.73 [1.95-7.14]) after adjustment by clinical confounders. The addition of the panel to clinical predictors significantly improved areas under the curve of the receiver operating characteristic curves in both cases. Conclusions Blood biomarkers could be useful for the early prediction of ADHF and RTI. Future studies should assess the usefulness of these panels in front of patients experiencing stroke with respiratory symptoms such as dyspnea.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Blood Biomarker Panels for the Early Prediction of Stroke‐Associated Complications

  • Faura Llorens, Julia
  • Bustamante Rangel, Alejandro
  • Reverté, Silvia
  • Garcia Berrocoso, Teresa
  • Millán Torné, Mònica
  • Castellanos, Mar
  • Ventura Ripoll, Oriol
  • Rubiera Del Fueyo, Marta Aurora
  • Montaner Villalonga, Joan
Biomarkers; Stroke; Stroke‐associated infection, Biomarcadors; Ictus; Infecció associada a un ictus, Biomarcadores; Ictus; Infección asociada a un ictus, Background Acute decompensated heart failure (ADHF) and respiratory tract infections (RTIs) are potentially life‐threatening complications in patients experiencing stroke during hospitalization. We aimed to test whether blood biomarker panels might predict these complications early after admission. Methods and Results Nine hundred thirty‐eight patients experiencing ischemic stroke were prospectively recruited in the Stroke‐Chip study. Post‐stroke complications during hospitalization were retrospectively evaluated. Blood samples were drawn within 6 hours after stroke onset, and 14 biomarkers were analyzed by immunoassays. Biomarker values were normalized using log‐transformation and Z score. PanelomiX algorithm was used to select panels with the best accuracy for predicting ADHF and RTI. Logistic regression models were constructed with the clinical variables and the biomarker panels. The additional predictive value of the panels compared with the clinical model alone was evaluated by receiver operating characteristic curves. An internal validation through a 10‐fold cross‐validation with 3 repeats was performed. ADHF and RTI occurred in 19 (2%) and 86 (9.1%) cases, respectively. Three‐biomarker panels were developed as predictors: vascular adhesion protein‐1 >5.67, NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) >4.98 and d‐dimer >5.38 (sensitivity, 89.5%; specificity, 71.7%) for ADHF; and interleukin‐6 >3.97, von Willebrand factor >3.67, and d‐dimer >4.58 (sensitivity, 82.6%; specificity, 59.8%) for RTI. Both panels independently predicted stroke complications (panel for ADHF: odds ratio [OR] [95% CI], 10.1 [3–52.2]; panel for RTI: OR, 3.73 [1.95–7.14]) after adjustment by clinical confounders. The addition of the panel to clinical predictors significantly improved areas under the curve of the receiver operating characteristic curves in both cases. Conclusions Blood biomarkers could be useful for the early prediction of ADHF and RTI. Future studies should assess the usefulness of these panels in front of patients experiencing stroke with respiratory symptoms such as dyspnea., This project received funding from Instituto de Salud Carlos III (ISCIII) [DTS14/00004, PI17/02130], co‐financed by the European Regional Development Fund (FEDER), and from Fundació La Marató de TV3 [201706] and the European Union's Horizon 2020 research and innovation program [754517]. Neurovascular Research Laboratory takes part into the Spanish stroke research network INVICTUS+ (RD16/0019/0021). The funders had no role in the study design and conduction.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Blood Biomarker Panels for the Early Prediction of Stroke-Associated Complications

  • Faura, Júlia|||0000-0002-8436-1377
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Reverté, Silvia|||0000-0002-2052-9978
  • García-Berrocoso, Teresa|||0000-0001-7387-7389
  • Millán Torné, Mònica|||0000-0002-4692-5936
  • Castellanos, María del Mar|||0000-0003-3116-1352
  • Lara-Rodríguez, Blanca|||0009-0003-4534-9687
  • Zaragoza, Josep
  • Ventura, Oriol
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • van Eendenburg, Cecile
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • López-Cancio, Elena|||0000-0001-5757-9074
  • Cánovas Verge, David|||0000-0002-3483-8106
  • Serena, Joaquín|||0000-0002-4478-7744
  • Rubiera Del Fueyo, Marta A.|||0000-0001-8100-9477
  • Dávalos, Antoni|||0000-0003-2949-5679
  • Montaner, Joan|||0000-0003-4845-2279
Acute decompensated heart failure (ADHF) and respiratory tract infections (RTIs) are potentially life-threatening complications in patients experiencing stroke during hospitalization. We aimed to test whether blood biomarker panels might predict these complications early after admission. Nine hundred thirty-eight patients experiencing ischemic stroke were prospectively recruited in the Stroke-Chip study. Post-stroke complications during hospitalization were retrospectively evaluated. Blood samples were drawn within 6 hours after stroke onset, and 14 biomarkers were analyzed by immunoassays. Biomarker values were normalized using log-transformation and Z score. PanelomiX algorithm was used to select panels with the best accuracy for predicting ADHF and RTI. Logistic regression models were constructed with the clinical variables and the biomarker panels. The additional predictive value of the panels compared with the clinical model alone was evaluated by receiver operating characteristic curves. An internal validation through a 10-fold cross-validation with 3 repeats was performed. ADHF and RTI occurred in 19 (2%) and 86 (9.1%) cases, respectively. Three-biomarker panels were developed as predictors: vascular adhesion protein-1.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Blood Biomarker Panels for the Early Prediction of Stroke‐Associated Complications

  • Faura Llorens, Julia
  • Bustamante Rangel, Alejandro
  • Reverté, Silvia
  • Garcia Berrocoso, Teresa
  • Millán Torné, Mònica
  • Castellanos, Mar
  • Ventura Ripoll, Oriol
  • Rubiera Del Fueyo, Marta Aurora
  • Montaner Villalonga, Joan
Biomarkers; Stroke; Stroke‐associated infection, Biomarcadors; Ictus; Infecció associada a un ictus, Biomarcadores; Ictus; Infección asociada a un ictus, Background Acute decompensated heart failure (ADHF) and respiratory tract infections (RTIs) are potentially life‐threatening complications in patients experiencing stroke during hospitalization. We aimed to test whether blood biomarker panels might predict these complications early after admission. Methods and Results Nine hundred thirty‐eight patients experiencing ischemic stroke were prospectively recruited in the Stroke‐Chip study. Post‐stroke complications during hospitalization were retrospectively evaluated. Blood samples were drawn within 6 hours after stroke onset, and 14 biomarkers were analyzed by immunoassays. Biomarker values were normalized using log‐transformation and Z score. PanelomiX algorithm was used to select panels with the best accuracy for predicting ADHF and RTI. Logistic regression models were constructed with the clinical variables and the biomarker panels. The additional predictive value of the panels compared with the clinical model alone was evaluated by receiver operating characteristic curves. An internal validation through a 10‐fold cross‐validation with 3 repeats was performed. ADHF and RTI occurred in 19 (2%) and 86 (9.1%) cases, respectively. Three‐biomarker panels were developed as predictors: vascular adhesion protein‐1 >5.67, NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) >4.98 and d‐dimer >5.38 (sensitivity, 89.5%; specificity, 71.7%) for ADHF; and interleukin‐6 >3.97, von Willebrand factor >3.67, and d‐dimer >4.58 (sensitivity, 82.6%; specificity, 59.8%) for RTI. Both panels independently predicted stroke complications (panel for ADHF: odds ratio [OR] [95% CI], 10.1 [3–52.2]; panel for RTI: OR, 3.73 [1.95–7.14]) after adjustment by clinical confounders. The addition of the panel to clinical predictors significantly improved areas under the curve of the receiver operating characteristic curves in both cases. Conclusions Blood biomarkers could be useful for the early prediction of ADHF and RTI. Future studies should assess the usefulness of these panels in front of patients experiencing stroke with respiratory symptoms such as dyspnea., This project received funding from Instituto de Salud Carlos III (ISCIII) [DTS14/00004, PI17/02130], co‐financed by the European Regional Development Fund (FEDER), and from Fundació La Marató de TV3 [201706] and the European Union's Horizon 2020 research and innovation program [754517]. Neurovascular Research Laboratory takes part into the Spanish stroke research network INVICTUS+ (RD16/0019/0021). The funders had no role in the study design and conduction.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Prevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation: Rationale and Design for PRESTIGE-AF Trial

  • Heuschmann, Peter
  • Malzahn, Uwe
  • Hügen, Klemens
  • Montaner Villalonga, Joan
  • Korompoki, Eleni
  • Harvey, Kirsten
  • Fiessler, Cornelia
Prevention of stroke; Intracerebral haemorrhage; Atrial fibrillation, Prevenció de l'ictus; Hemorràgia intracerebral; Fibril·lació auricular, Prevención del ictus; Hemorragia intracerebral; Fibrilación auricular, Adequate secondary prevention in survivors of intracerebral hemorrhage (ICH) who also have atrial fibrillation (AF) is a long-standing clinical dilemma because these patients are at increased risk of recurrent ICH as well as of ischemic stroke. The efficacy and safety of oral anticoagulation, the standard preventive medication for ischemic stroke patients with AF, in ICH patients with AF are uncertain. PRESTIGE-AF is an international,phase3b,multi-center,randomized,open,blindedend-pointassessment (PROBE)clinical trial that compared the efficacyandsafetyofdirectoralanticoagulants (DOACs) with no DOAC(either no antithrombotic treatment or any antiplatelet drug). Randomization occurred in a 1:1 ratio and stratification was based on ICH location and sex. The two co-primary binary endpoints included ischemic stroke and recurrent ICH which will be analyzed hierarchically according to the intention-to-treat principle. Secondary efficacy endpoints encompassed all-stroke and systemic embolism, allcause and cardiovascular mortality, major adverse cardiac events, and net clinical benefit. Secondary safety endpoints included any major hemorrhage and intracranial hemorrhage. All outcome events were adjudicated by an independent committee. Results of PRESTIGE-AF are expected to support risk-adjusted secondary prevention in ICH survivors with AF and to inform clinical guideline recommendations., PRESTIGE-AF is a clinical trial of investigational medicinal products sponsored by Imperial College London. The PRESTIGE-AF trial is managed by the coordinating team at Imperial College London. The data management, central data monitoring, and statistical analysis are provided by The Clinical Trial Centre at the University Hospital of Wuerzburg. The clinical trial is part of a Horizon 2020 project with a consortium of 12 institutions across Europe. This project has received funding from the European Union's Horizon 2020 research and innovation program under Grant Agreement No. 754517.